Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Victoria Vakiener Sells 1,799 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Victoria Vakiener sold 1,799 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total transaction of $41,934.69. Following the completion of the transaction, the director now directly owns 30,205 shares in the company, valued at $704,078.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Arrowhead Pharmaceuticals Stock Up 2.9 %

NASDAQ:ARWR opened at $25.16 on Tuesday. The firm has a 50-day moving average price of $27.23 and a 200 day moving average price of $28.75. The firm has a market capitalization of $3.12 billion, a PE ratio of -9.05 and a beta of 0.78. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $20.67 and a 12-month high of $41.36.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, February 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.46). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 90.77%. The firm had revenue of $3.55 million during the quarter, compared to analyst estimates of $35.60 million. During the same quarter in the prior year, the firm posted ($0.39) EPS. The firm’s revenue for the quarter was down 94.3% on a year-over-year basis. On average, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.7 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ARWR shares. Morgan Stanley lifted their price target on Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the company an “equal weight” rating in a report on Wednesday, February 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $50.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 7th. Citigroup lifted their price objective on shares of Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the company a “neutral” rating in a research note on Wednesday, February 7th. Finally, HC Wainwright reissued a “buy” rating and set a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $50.80.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ARWR. Texas Permanent School Fund Corp increased its holdings in shares of Arrowhead Pharmaceuticals by 17.3% in the first quarter. Texas Permanent School Fund Corp now owns 108,433 shares of the biotechnology company’s stock valued at $3,101,000 after purchasing an additional 16,008 shares in the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the 1st quarter valued at $2,068,000. Mutual of America Capital Management LLC raised its position in shares of Arrowhead Pharmaceuticals by 11.5% during the first quarter. Mutual of America Capital Management LLC now owns 73,826 shares of the biotechnology company’s stock worth $2,111,000 after acquiring an additional 7,597 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Arrowhead Pharmaceuticals by 67.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 327,782 shares of the biotechnology company’s stock valued at $9,375,000 after acquiring an additional 131,797 shares during the period. Finally, Retirement Systems of Alabama boosted its holdings in Arrowhead Pharmaceuticals by 6.5% in the first quarter. Retirement Systems of Alabama now owns 348,784 shares of the biotechnology company’s stock valued at $9,975,000 after acquiring an additional 21,331 shares during the last quarter. 62.61% of the stock is owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.